Immatics Appoints Biotech Executive Eliot Forster to Board of Directors
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and develop…
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and develop…
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and develop…
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-c…
Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financi…
Immatics Biotechnologies GmbH, a leading company in the field of cancer immunotherapy announces the appointment of Katin…
. - immatics' lead cancer vaccine IMA901 to report interim phase 3 data in 2014 and final data in 2015 - Funding secur…
. - immatics' erwartet für seinen führenden Impfstoff IMA901 in 2014 erste Interimsdaten der Phase 3-Zulassungsstudie u…
immatics biotechnologies GmbH, ein biopharmazeutisches Unternehmen, das innovative therapeutische Impfstoffe gegen Krebs…
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that…